Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: LDL Clear all
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 2 Interventional Results available

Randomized Study of Obicetrapib in Combination With Ezetimibe

NCT04770389
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib 5mg, Ezetimibe 10mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Lincoln, California • Evanston, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 7, 2026, 5:04 AM EST
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
101
States / cities
Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 7, 2026, 5:04 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Almonds on Cardiovascular Risk Factors

NCT01101230
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Almonds
Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 2 Interventional

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

NCT00404001
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MD-0727
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Nov 7, 2026, 5:04 AM EST
Completed Not applicable Interventional Results available

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

NCT00762229
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Ezetimibe 10 mg, Ezetimibe 5 mg
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Nov 7, 2026, 5:04 AM EST
Completed Not applicable Interventional

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

NCT01152957
View directory record Official record
Conditions
Diabetes, Heart Disease, Hypertension
Interventions
CARIÑO Project, Enhanced Usual Care
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Nov 7, 2026, 5:04 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

NCT03067441
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 2 Interventional Results available

A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654
View directory record Official record
Conditions
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Nov 7, 2026, 5:04 AM EST
Recruiting No phase listed Observational

A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet

NCT07137286
View directory record Official record
Conditions
LDL Hyper-responsiveness
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 7, 2026, 5:04 AM EST
Terminated Phase 4 Interventional Results available

Impact of LDL-cholesterol Lowering on Platelet Activation

NCT03331666
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Evolocumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Nov 7, 2026, 5:04 AM EST
Not yet recruiting Phase 2 Interventional

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

NCT07839936
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions
VERVE-102, Placebo
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
DeSoto, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 7, 2026, 5:04 AM EST
Completed No phase listed Observational Results available

Lipid Metabolism in Gestational Diabetes

NCT00534105
View directory record Official record
Conditions
Gestational Diabetes, Hyperlipidemia
Interventions
Total Cholesterol, Triglyceride, HDL, LDL
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 2 Interventional

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00280995
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Nov 7, 2026, 5:04 AM EST
Completed Not applicable Interventional Results available

A Community Wellness Program for Adults Living With Long-term Physical Disability

NCT03653390
View directory record Official record
Conditions
Physical Disability
Interventions
EnhanceWellness for Disability (EW-D), Wellness Education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 64 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

NCT01849497
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab Pre-filled Syringe, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
21
States / cities
Encino, California • Thousand Oaks, California • Ventura, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Nov 7, 2026, 5:04 AM EST
Recruiting Not applicable Interventional

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

NCT06743659
View directory record Official record
Conditions
Familial Hypercholesterolaemia
Interventions
Alert-based computerized decision support
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Nov 7, 2026, 5:04 AM EST
Completed No phase listed Observational

Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients

NCT04148001
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
Not listed
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Nov 7, 2026, 5:04 AM EST
Completed Phase 1 Interventional

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

NCT01845428
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Pravastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 7, 2026, 5:04 AM EST